E2 Dispensing Webinar

Welcome to our E2 Dispensing Webinar series. Over the next few weeks, we will release 8 episodes, introducing the E2 dispensing methodology and ecosystem to all. These webinars are aimed at everyone involved in clinical research and clinical trials. We will go into RxE2’s innovative and disruptive way of simplifying decentralized clinical trials and more specifically introducing…

How to boost excellence and innovation in clinical supply chains

By: Gerald E. Finken Originally posted on Linkedin In November 2021, McKinsey & Company published an interesting article on how to boost excellence and innovation in clinical supply chains that are relevant to today’s industry practices. What I found most compelling was how a best-in-class clinical supply chain could change and adapt to accommodate decentralized clinical trials (DCTs)…

The Impact of Decentralized Clinical Trials on the Investigational Drug Supply Chain: Making Clinical Supplies Patient-Centric

By: Gerald E. Finken The introduction of decentralized clinical trials (“DCTs”) into clinical research has, in recent years, focused on the use of technology and telehealth to improve the clinical trial experience for patients. The proponents of the DCT model have heralded it, and rightly so, with improving study recruitment, providing better patient diversity, and…

Everyone Everywhere with Gerald Finken | Episode 1

Join us Live with our guest Tripp Logan, COO ESPhA, for a conversation on State Pharmacy Regulations and Decentralized Trials. The Enhanced Service Pharmacy Alliance (ESPhA) is the pharmacy industry’s only next-generation pharmacy service consulting firm. ESPhA’s mission is to foster an alliance of quality-driven, patient-focused pharmacists, pharmacies, consultants, vendors, and payer partners to collaborate…

The Digital Executive | Episode 66 PODCAST

Serial entrepreneur and CEO of RxE2, Gerald Finken, joins Coruzant Technologies for the Digital Executive podcast. He shares his secret to success, which includes lifelong learning and his determination to succeed when told no or it can’t be done. This is displayed by the innovation that he brings to clinical trials as an experienced pharmacist.